Search company, investor...
Search

Founded Year

2015

Stage

Series G - II | Alive

Total Raised

$1.07B

Valuation

$0000 

Last Raised

$200M | 2 yrs ago

Mosaic Score

+30 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Tempus Headquarters Location

600 West Chicago Avenue Suite 510

Chicago, Illinois, 60654,

United States

833-514-4187

ESPs containing Tempus

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Biopharma Tech

These companies provide anonymized patient datasets and supporting analytical tools — such as genomic variant analysis software — to support drug target discovery and patient stratification. The majority of vendors in this space provide population genomic data, however some are now starting to incorporate other data sources, such as EHR, transcriptomic, and proteomic data.

Tempus named as Leader among 14 other companies, including BC Platforms, DNAnexus, and Genomenon.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Tempus's Products & Differentiation

See Tempus's products and how their products differentiate from alternatives and competitors

  • Sequencing

    Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities

    Differentiation

    NGS tests to support clinical trial sequencing 

    + biopharma partnerships 

    + oncologists have used our offerings 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Tempus

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tempus is included in 16 Expert Collections, including Digital Health.

D

Digital Health

21,952 items

Startups recreating how healthcare is delivered

U

Unicorns- Billion Dollar Startups

1,190 items

A

AI 100

99 items

C

Clinical Trials Tech

329 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

A

Artificial Intelligence

9,391 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

Latest Tempus News

Precedent Issued On “The Vaccine”

Sep 23, 2022

To embed, copy and paste the code into your website or blog: <iframe frameborder="1" height="620" scrolling="auto" src="//www.jdsupra.com/post/contentViewerEmbed.aspx?fid=c9b7a704-2f2a-4354-9f2b-112365cd6f96" style="border: 2px solid #ccc; overflow-x:hidden !important; overflow:hidden;" width="100%"></iframe> Tempus fugit. It was December 2020 when the FDA issued its first approval for a Covid vaccine. Perhaps this writer was the naïve one but I never thought a vaccine to ‘prevent’ a very deadly disease that has today afflicted nearly 1/3 of the U.S. population and killed a million of us would unleash a war pitting public health against civil liberties. But, I digress. The vaccine wars have been played out in courtrooms throughout America. Separated parents decided that their childrens’ fears about succumbing to an airborne disease decided their children also needed to witness courtroom battles where the deck was heavily stacked. Anyone who went to court to prevent a child from being vaccinated did so with little chance of prevailing. What judge in his or her right mind leaves a child exposed to death or serious illness in a setting where the Food and Drug Administration issued reports finding that there was a safe and efficacious means to prevent the illness? The writer did hear of cases where vaccine was denied but only in a setting where the child had pre-existing conditions which made the vaccine more dangerous than exposure to coronavirus. Law moves slowly and that is not always a bad thing. In May, 2021 Pfizer’s vaccine secured FDA approval in children aged 12 and above. In Butler County the parents of S.B. shared legal custody of their daughter, born in May 2008. On August 26, 2021 mother filed for permission to have the child vaccinated. In November she amended that petition to reflect endorsement of vaccination by the pediatrician and the local schools. The local district insisted on vaccination as a condition to return to the classroom. The child had been vaccinated against other contagious diseases but Father opposed this one. A hearing was schedule and mother proposed to admit a document issued by a non treating pediatrician. Father filed a motion to prevent the testimony because the written report was not specific to the child but a generic publication titled “Covid-19 Talking Points.” It expressed no opinion related to the subject child and the physician had not evaluated the child. The court granted the petition and mother filed an amended report wherein the physician stated an opinion based upon review of the child’s medical history. On December 10, 2021 the physician was permitted to testify. His qualifications were not challenged as she headed the vaccine response for a local health system. His testimony appears to have mirrored what the FDA published and she saw no contraindications based upon the child’s history. There had been no actual physician exam of the child. The medical conclusion was that vaccination was a sound medical procedure. Father appears to have represented himself. His defense was essentially built around the fact that FDA’s authorization was provisional and that long term effects were not ascertainable. Five days after the hearing the court granted mother’s request. Father’s appeal contended the court had not issued findings of fact and the absence of a physician examination of the child. The Superior Court acknowledged that where custody is being decided or modified the analysis of all statutory factors is required. But this was a one issue special relief petition and not a review of the custodial arrangements themselves. Thus S.W.D. v. S.A.R., 96 A.3d 396 (Pa.Super. 2014) and  M.O. v. J.T.R., 85 A.3d 1058 (Pa. Super. 2014) make clear that full factor analysis is superfluous. Nor need the court make finding of facts in deciding special relief petitions. But those findings are furnished in the trial court’s opinion. The father also asserted that the expert testimony should have been precluded because the court had originally denied the testimony. The Superior Court notes that while the original report may have been defective, the revised report met the standard of an expert report. Father’s contentions that the report was incomplete failed because he stipulated to the physician’s expertise. Father’s professed concerns about secondary effects were considered as make weight in a setting where he was not part of the wellness appointments the child had with her pediatrician before the onset of the pandemic. As happened in many of the cases we have read and heard about the parent opposing vaccination did not produce medical testimony speaking directly to contraindications. The expert’s testimony on a subject like this does not require a comprehensive analysis of the child’s genetic and medical history to be admissible and accepted by the courts. There are no surprises in Judge Megan King’s published opinion. It was a good case to publish because it is emblematic of what has played out in many courtrooms where this issue has been litigated. The child’s pediatrician did testify but said no more than that there were no contraindications specific to this child. The case was viewed with an abuse of discretion standard and father produced no evidence which effectively rebutted mother’s case. L.L.B. v. T.R.B. 2022 Pa. Super. 161    (Sept. 21, 2022)  Bender, Dubrow & King w/o dissent/concurrence

Tempus Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Tempus Rank

  • When was Tempus founded?

    Tempus was founded in 2015.

  • Where is Tempus's headquarters?

    Tempus's headquarters is located at 600 West Chicago Avenue, Chicago.

  • What is Tempus's latest funding round?

    Tempus's latest funding round is Series G - II.

  • How much did Tempus raise?

    Tempus raised a total of $1.07B.

  • Who are the investors of Tempus?

    Investors of Tempus include T. Rowe Price, Baillie Gifford & Co., Franklin Templeton, Novo Holdings, Eric Lefkofsky and 7 more.

  • Who are Tempus's competitors?

    Competitors of Tempus include Atropos Health, Syapse, Lunit, Owkin, NuProbe, Perthera, Mendel.ai, Zephyr AI, ConcertAI, AllStripes and 38 more.

  • What products does Tempus offer?

    Tempus's products include Sequencing and 4 more.

  • Who are Tempus's customers?

    Customers of Tempus include Genmab, Bayer, Kronos and Leap.

You May Also Like

Owkin Logo
Owkin

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology. The company was founded in 2016 and is based in New York, New York.

ConcertAI Logo
ConcertAI

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

Evidation Logo
Evidation

Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.

Aetion Logo
Aetion

Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.

Syapse Logo
Syapse

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations. The company was formerly known as BDLicense. Syapse was founded in 2008 and is based in San Francisco, California.

Verana Health Logo
Verana Health

Verana Health assembles clinical databases in medicine to empower physicians and accelerate research for patients. The databases produce drug lifecycle and medical practice insights.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.